Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Quiz|Articles|October 6, 2026
Dermatology Times Spot Test: October 6, 2026
Author(s)Shannon Heaning, Content Associate
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This edition revisits our EADV 2026 coverage of delgocitinib in chronic hand eczema. Test your knowledge of REACHED and DELTA TEEN, then read
Do you have a set of quiz questions to share? Contact editor Shannon Heaning at Sheaning
Which description best matches the REACHED study?
At week 8 in the REACHED interim analysis, what percentage of patients were assessed as clear or almost clear?
In the DELTA TEEN post hoc symptom analysis, improvements in itch and pain were observed as early as which time point?
Advertisement
Related to this article
Explore dermatology conferences and meetings taking place this October, including clinical updates, skin of color education, and pediatric dermatology research.
New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.
From next-generation oral therapies and long-term disease control to precision medicine, EADV 2026 highlighted a dermatology landscape increasingly focused on deeper, durable, and individualized outcomes.
The final day of EADV 2026 explored precision medicine, molecular profiling, atopic dermatitis research, real-world evidence, and emerging approaches to individualized dermatologic care.
New EADV 2026 data highlighted real-world outcomes in adults with chronic hand eczema and improvements in itch, pain, and quality of life among adolescents treated with delgocitinib cream.
Day 3 of EADV 2026 featured long-term psoriasis data, advances in hidradenitis suppurativa, evolving approaches to atopic dermatitis, and late-breaking research.
Seven presentations will highlight phase 3 maintenance and induction findings, 3-year phase 2 data, and preclinical research evaluating obefazimod in ulcerative colitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 in Review: The Research and Therapeutic Advances That Defined the Congress
2
EADV 2026 Day 3: Long-Term Psoriasis Data and Emerging Therapeutic Targets Take Focus
3
Dermatology Times Monthly FDA and Pipeline Review: September 2026
4
Obefazimod Data Across Phase 3 and Long-Term Studies to Be Presented at UEG Week 2026
5